Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 22 April 2026 ASX RELEASE ACCENT TRIAL MATURE DATA PRESENTED AT INTERNATIONAL CONFERENCE HIGHLIGHTS • Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting • The ACCENT trial investigates the combination of narmafotinib with standard-of-care chemotherapy • The data presented includes additional analysis of the promising efficacy and survival data reported last month MELBOURNE, AUSTRALIA: Amplia Therapeutics limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) announces that an oral presentation highlighting mature data from the Company’s ACCENT trial in metastatic pancreatic cancer is being delivered today at the annual meeting of the AACR. The presentation includes more detailed analysis of the recently reported data from the ACCENT study, which is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of- care chemotherapy. The presentation is included as part of a mini-symposium entitled Advances in Precision Oncology being held in the San Diego Convention Center, San Diego USA, and will be delivered by Amplia’s Director of Translational Biology, Dr Terrie-Anne Cock, at 3:44 pm local time. A copy of the slides is included with this announcement. The key points from the presentation are: • Narmafotinib displays a manageable toxicity profile, with no significant tolerability burden over chemotherapy alone • Independent (central) reading of data identified 5 confirmed Complete Responses (CR’s) from 64 patients, an 8% CR rate compared to a 0.2% rate for chemotherapy alone • A response rate of 36% is observed (23 of 64 patients); 42% if unconfirmed responses included • A Disease Control Rate (DCR) of 70% was determined, compared to 50% for chemotherapy alone • Median overall survival (mOS) was found to be 11.1 months, while median progression-free survival (mPFS) was 7.7 months, both showing improvements of over two months compared to chemotherapy alone • A trend to improved Overall Survival is observed when comparing Stable Disease, Partial Response and Complete Response patients • The combined efficacy data is superior to chemotherapy alone across all measures despite the intermittent narmafotinib dosing schedule employed (12 days of each 28 day treatment cycle) • Subsequent trials will employ a daily dosing regimen of narmafotinib given the tolerability observed to date, which may lead to improved responses Dr Chris Burns, CEO and Managing Director of Amplia, commented: “We are excited to present this mature ACCENT data at the AACR annual meeting. Being able to present the extremely promising clinical responses to colleagues and peers at one of the world’s most prestigious oncology conferences allows us to demonstrate the potential narmafotinib has in the treatment of this terrible disease. We are now focused on building on this promising data with additional clinical studies, including a pivotal study based on the ACCENT trial, as well as combination studies with the exciting new class of drugs called kRAS inhibitors.” This ASX announcement was approved and authorized for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: Tom Trezona, H^CK Acting MD tom@hck.digital +61 411 235 692 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a response rate of 31%, superior to chemotherapy alone and an interim PFS of 7.6 months has been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at two sites in Australia, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients. About the ACCENT Trial The ACCENT trial is entitled ‘A Phase 1b/2a, Multicenter, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients’. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and safety and tolerability, with secondary endpoints including Progression Free Survival (PFS) and Overall Survival (OS). The trial is being conducted at seven sites in Australia and five sites in South Korea. More information about the ACCENT trial can be found via the ACCENT trial site, the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298. Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b/2a study: Interim analysis Terrie-Anne Cock PhD Amplia Therapeutics Australia ASX:ATX | OTCQB:INNMF FOCAL ADHESION KINASE INHIBITION IN CANCER FAK enzyme overactive in pancreatic cancer Modified from Journal for ImmunoTherapy of Cancer (2017) 5:17 FAK levels are elevated in pancreatic cancer • Correlate with worse patient outcomes FAK is a cellular stress-buffer that sustains tumor survival especially under therapeutic stress FAK overactivity in both cancer cells and fibroblasts • Causes fibrosis and immune suppression • Tumor growth • Metastasis • Treatment resistance 2 NARMAFOTINIB A Potent and Selective FAK Inhibitor Drug-like small molecule • Highly potent and highly selective FAKi • Pharmacokinetic (PK) profile supports oral once-a- day dosing (t½ ~20 h) • Dose-proportional PK • Patient population not limited by genetics Safe to combine with other medicines • Low risk of significant drug-drug interactions (CYPs: IC50 > 20 μM) • Ability to combine with a broad range of standard of care therapies Evidence of FAK target engagement preclinically and in the clinic 3 ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea * ORR - Objective Response Rate; RECIST - Response Evaluation Criteria in Solid Tumours, Eur J Canc. 2009, 45, 228-247. OBJECTIVE • To determine safety and efficacy of narmafotinib in combination with gemcitabine and nab- paclitaxel (Gem/nab-P) • Patients with newly diagnosed metastatic disease PRIMARY ENDPOINTS • Safety, Tolerability • ORR (RECIST 1.1)* ADDITIONAL ENDPOINTS • Progression free survival (PFS) • Overall Survival (OS) • Disease Control Rate (DCR) 4 ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea 7 days priming prior to Gem/nab-P on Cycle 1 Day 1 4 days of dosing prior to each Gem/nab-P thereafter 12 days out of 28-day cycle 43% coverage after cycle 1 5 ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea Part A: Dose escalation to selectdose for Part B • 3 patients at 100 mg • 3 patients at 200 mg • 9 patients at 400 mg Part B: Single arm, non-blinded Simon 2-Stage design • 55 patients at 400 mg Total of 64 patients at 400 mg Demographics All 400 mg patients Patient # (total study) 64 Geographic area (%) Australia (52%) / Korea (48%) Female (%) 32 (50%) Age median (min-max) 63y (37 – 87) ECOG PS 0 21 (33%) ECOG PS 1 43 (67%) Ethnic background Caucasian 28 (44%) Asian 34 (53%) Australian Aborigine / Torres Strait Islander 1 (1.6%) Unknown 1 (1.6%) 6 Abstract data • Investigator read • Requested in real time to assess patient progress • RECIST 1.1 analysis standard in clinical trials NOT standard in clinical practice ACCENT TRIAL IN PANCREATIC CANCER RECIST 1.1 analysis ACCENT Data presented today • Independent review (central read) performed by specialist global contract organization • Two independent experts • Blinded to investigator assessment and blinded to patient clinical data 7 ACCENT TRIAL IN PANCREATIC CANCER Narmafotinib treatment results in negligible extra patient burden PIVOTAL STUDY Adverse Event (AE) Grade ≥ 3 Narmafotinib +Gem/nab-P (ACCENT N=64) Gem/nab-P (MPACT; N=421) Gem/nab-P (NAPOLI 3; N=379) Neutropenia 39% 38% 39% Anemia 17.2% 13% 18% Diarrhea 6.3% 6% 5% Peripheral neuropathy 6.3% 17% 6% Vomiting 3.1% NR 2% Febrile Neutropenia 4.7% 3% NR Thrombocytopenia 3.1% 13% NR Fatigue NR 17% 5% Hypokalemia NR NR 4% Nausea 4.7% NR 3% NR: not reached; Common generally refers to TRAEs in ≥ 5% of patients (%); For ACCENT: Peripheral Neuropathy includes events of both Peripheral Sensory Neuropathy and Neuropathy Sensory; Neutropenia includes events of both Neutropenia and Neutrophil Count Decreased; Thrombocytopenia includes events of both Thrombocytopenia and Platelet Count Decreased; Not all pivotal trials reported on all AE’s or used fully consistent terminology; Differences exist between trial designs, subject characteristics and other factors, and caution should be exercised when comparing data across studies: MPACT Von Hoff et al., N Engl J Med. 2013 and NAPOLI Wainberg et al., Lancet 2023. Interim data based on safety data cut-off 20 Jan 2026. 8 ACCENT TRIAL IN PANCREATIC CANCER Narmafotinib treatment results in negligible extra patient burden Abbreviations; N = number of participants. Interim data based on safety data cut-off 20 Jan 2026 Narmafotinib-related TEAEs in were mostly gastrointestinal events predominately mild to moderate Narmafotinib Related Adverse Events Any grade ( ≥ 5%) Narmafotinib 400 mg (N=64) N (%) Nausea 19 (29.7) Vomiting 13 (20.3) Diarrhea 12 (18.8) Gastroesophageal reflux disease 7 (10.9) Fatigue 7 (10.9) 9 ACCENT TRIAL IN PANCREATIC CANCER Exceptional complete response rate ACCENT Trial (Narmafotinib/ Gem/nab-P) (N=64) MPACT Trial (Gem/nab-P) CR 5 (8%) 0.2% PR 18 (28%) 23% SD 22 (34%) 27% PD 6 (9%) 20% NE 13 (20%) 30% ORR 36% 23% DCR 70% 50% Excellent response rate observed • 5 confirmed Complete Responses (CR) • 18 confirmed Partial Responses (PR); Incl. 1 patient with pathological Complete Response (pCR) • Confirmed objective response rate (ORR) of 36%. Unconfirmed objective response rate 42% • Disease control rate (DCR) of 70% • 12 patients on trial >12 months* • 4 patients are still on study Interim data based on central read data cut-off 17 March 2026. All responses were confirmed, and efficacy was assessed using an intention-to-treat analysis in accordance with RECIST criteria. NE - Non-evaluable. N = number of participants. * Patients continued on trial based on investigator read RECIST results 10 ACCENT TRIAL IN PANCREATIC CANCER Enhanced depth of response -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 Best change from baseline (%) (target lesions) Progressive Disease Stable Disease Complete Response Partial Response Pathological Complete Response Individual patients Interim data based on central read data cut-off 17 March 2026. All responses were confirmed, and efficacy was assessed using an intention-to-treat analysis in accordance with RECIST criteria. Non-evaluable not shown Average tumor volume reduction of ~69% (PR and CR) Patient still on study 11 ACCENT TRIAL IN PANCREATIC CANCER Early and sustained deep tumor shrinkage 0 60 120 180 240 300 360 420 480 540 600 -100 -80 -60 -40 -20 0 20 40 60 Time to scan (from day -8) Target lesion: change from baseline (%) Interim data based on central read data cut-off 17 March 2026. All responses were confirmed, and efficacy was assessed using an intention-to-treat analysis in accordance with RECIST criteria. Non-evaluable not shown Key for overall response Black = PD Grey = SD Blue = PR Orange = pCR Purple = CR Open circles = patient still on study 12 Median Progression Free Survival (mPFS) • Currently determined at 7.7 months - substantially better than Gem/nab-P chemotherapy alone (5.5 months) • Improvement over FOLFIRINOX chemotherapy (6.4 months) ACCENT TRIAL IN PANCREATIC CANCER Improved PFS over chemotherapy alone ACCENT Trial (Narmafotinib + Gem/nab-P) MPACT Trial (Gem/nab-P) PRODIGE Trial (FOLFIRINOX) mPFS 7.7 months 5.5 months 6.4 months Interim data based on central read data cut-off 17 March 2026 0 2 4 6 8 10 12 14 16 18 20 22 24 0 10 20 30 40 50 60 70 80 90 100 Months Progression free survival (%) 13 Median Overall Survival (mOS) data • Currently determined at 11.1 months - substantially better than Gem/nab-P chemotherapy alone (8.5-9.2 months) • Comparable to FOLFIRINOX chemotherapy (11.1 months) ACCENT TRIAL IN PANCREATIC CANCER Improved overall survival – sustained response Interim data based on central read data cut-off 17 March 2026 0 2 4 6 8 10 12 14 16 18 20 22 24 0 10 20 30 40 50 60 70 80 90 100 Months Overall survival (%) ACCENT Trial (Narmafotinib + Gem/nab-P) MPACT Trial (Gem/nab-P) NAPOLI Trial (Gem/nab-P) mOS 11.1 months 8.5 months 9.2 months 14 Median Overall Survival (mOS) data • Currently determined at 11.1 months - substantially better than Gem/nab-P chemotherapy alone (8.5-9.2 months) • Comparable to FOLFIRINOX chemotherapy (11.1 months) ACCENT TRIAL IN PANCREATIC CANCER Improved overall survival – sustained response Interim data based on central read data cut-off 17 March 2026 0 6 12 18 24 CR PR SD PD Overall survival (months) White circles indicate patients known to be alive at recent follow up ACCENT Trial (Narmafotinib + Gem/nab-P) MPACT Trial (Gem/nab-P) NAPOLI Trial (Gem/nab-P) mOS 11.1 months 8.5 months 9.2 months 15 ACCENT TRIAL IN PANCREATIC CANCER Summary Deep and fast response Durable and sustained response Demonstrated tolerability 64 patients 400 mg • 5 CR • 18 PR (incl. 1 pCR) Improved PFS (7.7 mo) over Gem/nab-P and FOLFIRINOX 12 patients on trial >12 months Improved OS (11.1 mo) over Gem/nab-P Deep and sustained response for many patients Good tolerability profile Minimal additional burden on patients above standard of care In ACCENT, narmafotinib is dosed intermittently, subsequent studies including pivotal trials will utilise daily dosing, which may further enhance efficacy 16 Co-authors: S. Ananda, C. Lee, N. Pavlakis, J. Park, J. Kim, D. Lau, L. Lipton, A. Nagrial, W. Lee, H. Chan, D. Oh, W. Joubert, S. Kinkel, N. Kruger, C. Mulder, J. Lickliter, C. Burns We thank all investigators and site staff involved in the ACCENT trial We gratefully acknowledge the patients, their families and loved ones, whose participation in clinical research makes these advances possible ACKNOWLEDGMENTS